MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1.

ABSTRACT:

Background

Urinary bladder carcinoma stage T1 is an unpredictable disease that in some cases has a good prognosis with only local or no recurrence, but in others can appear as a more aggressive tumor with progression to more advanced stages. The aim here was to investigate stage T1 tumors regarding MDM2 promoter SNP309 polymorphism, mutations in the p53 gene, and expression of p53 and p16 measured by immunohistochemistry, and subsequently relate these changes to tumor recurrence and progression. We examined a cohort of patients with primary stage T1 urothelial carcinoma of the bladder and their tumors.

Methods

After re-evaluation of the original slides and exclusions, the study population comprised 141 patients, all with primary stage T1 urothelial carcinoma of the bladder.

SUBMITTER: Olsson H 

PROVIDER: S-EPMC3574032 | biostudies-literature | 2013 Jan

REPOSITORIES: biostudies-literature